<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00451412</url>
  </required_header>
  <id_info>
    <org_study_id>CMEX839BDE03</org_study_id>
    <nct_id>NCT00451412</nct_id>
  </id_info>
  <brief_title>A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center Comparison of the Efficacy and Safety of Certoparin (3000 U Anti-Xa o.d.) With Unfractionated Heparin (5000 IU t.i.d.) in the Prophylaxis of Thromboembolic Events in Acutely Ill Medical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to provide efficacy and safety data for certoparin in the prophylaxis
      of venous thromboembolism in immobilized, acutely ill medical patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of venous thromboembolism during treatment (proximal deep vein thrombosis, pulmonary embolism, death related to venous thromboembolism)</measure>
    <time_frame>20 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>proximal and distal deep vein thrombosis (DVT) (combined and separate) assessed by ultrasound screening,</measure>
    <time_frame>20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptomatic DVT,</measure>
    <time_frame>20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptomatic non-fatal pulmonary embolism (PE),</measure>
    <time_frame>20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>combination of proximal DVT, non fatal PE and death from all causes including PE</measure>
    <time_frame>20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VTE related death,</measure>
    <time_frame>20 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3254</enrollment>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Certoparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Unfractionated Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certoparin</intervention_name>
    <description>3000 U anti XA of certoparin in 0.3 ml solution, once daily</description>
    <arm_group_label>Certoparin</arm_group_label>
    <other_name>Sandoparin</other_name>
    <other_name>Embolex</other_name>
    <other_name>low molecular weight heparin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractionated Heparin</intervention_name>
    <description>solution, 5000 IU of unfractionated heparin in 0.3 ml, 3 times daily</description>
    <arm_group_label>Unfractionated Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hospitalized medical patients 70 years of age or older

          2. Acute medical illness with significant decrease in mobility expected for at least 4
             days (patient bedridden or only able to walk short distances)

          3. written informed consent

        Exclusion Criteria:

          1. immobilization longer than 3 days prior to randomization

          2. prior major surgery, trauma or invasive procedure within the last 4 weeks including
             any injuries or operation of central nervous system

          3. expected major surgical or invasive procedure within the next 3 weeks after
             randomization

          4. LMWH/heparin administration longer than 48 hours in the 5 days prior to randomization

          5. immobilization due to cast or fracture

          6. indication for anticoagulatory or thrombolytic therapy

          7. acute symptomatic DVT / PE

          8. known hypersensitivity to any of the study drugs or drugs with similar chemical
             structures

          9. Acute or history of heparin induced thrombocytopenia type II (HIT II)

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis investigative sites</name>
      <address>
        <city>NÃ¼rnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2007</study_first_submitted>
  <study_first_submitted_qc>March 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2007</study_first_posted>
  <last_update_submitted>July 24, 2012</last_update_submitted>
  <last_update_submitted_qc>July 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venous thromboembolism</keyword>
  <keyword>Medical patients</keyword>
  <keyword>Heparin</keyword>
  <keyword>Low molecular weight heparin</keyword>
  <keyword>Deep vein thrombosis</keyword>
  <keyword>Certoparin</keyword>
  <keyword>Embolism and Thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Certoparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

